Advertisement

Topics

Janssen-Cilag AG Company Profile

02:36 EDT 19th June 2018 | BioPortfolio

NIL

Location

Sihlbruggstrasse 111
Baar
6340
France

Contact

Phone: 41 (41) 767 34 34
Fax: 41 (41) 767 34 00
Email: info@jacch.jnj.com.


News Articles [273 Associated News Articles listed on BioPortfolio]

Saliva-based diagnostics offer possibility to detect HPV-induced throat cancer

This follows the extension of a QUT collaboration with Johnson & Johnson Innovation, Janssen Vaccines & Prevention, and Janssen Cilag Pty Ltd.

French Competition Body Fines Janssen €25m For Delaying Generic Durogesic

Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to...   

Saliva test aims to detect HPV throat cancers

(Queensland University of Technology) A QUT researcher is developing a simple saliva test to detect Human papilloma virus (HPV) in throat cancers.This follows the extension of a QUT collaboration with...

France fines J&J 25 million Euro for blocking generics

A fine of Euros 25 million was imposed on Janssen-Cilag and its parent company Johnson & Johnson (J&J) by the French Competition Authority on 20 December 2017. This occurred in response to a r...

Probi & Cilag sign long-term agreement to develop probiotic product

Swedish bioengineering company, Probi, has signed a long-term agreement with Cilag, which is a member of the Johnson & Johnson family of companies, for the development of a probiotic product.

Janssen strengthens immunotherapy capabilities with BeneVir acquisition

Janssen Biotech has entered into a definitive agreement to acquire BeneVir Biopharm, a deal which looks to advance Janssenâs immunotherapy platform and capabilities.

Fujirebio and Janssen Partner to Develop An Assay to Identify Patients that may Benefit from Janssen’s Investigational Alzheimer’s Disease Drug

MALVERN, Pa.–(BUSINESS WIRE)–Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fuji...

Genmab and Janssen Suffer Combination Therapy Setback

Janssen will discontinue a Phase I study testing Danish biotech Genmab’s blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma.  ...

Drugs and Medications [39 Associated Drugs and Medications listed on BioPortfolio]

Long last make up 02 (neo heliopan) [Janssen Cosmetics GmbH]

Drug Facts

Risperidone [WOCKHARDT USA LLC.]

These highlights do not include all the information needed to use risperidone oral solution safely and effectively. See full prescribing information for risperidone oral solution. Risperidone Oral Sol...

Risperidone [WOCKHARDT LIMITED]

These highlights do not include all the information needed to use risperidone oral solution safely and effectively. See full prescribing information for risperidone oral solution. Risperidone Oral Sol...

Stelara [Janssen Biotech, Inc.]

These highlights do not include all the information needed to use STELARA safely and effectively. See full prescribing information for STELARA. STELARA (ustekinumab) Injection, for subcutaneous useIn...

Nizoral [Ortho-McNeil-Janssen Pharmaceuticals, Inc.]

Nizoral (ketoconazole) 2% Shampoo

PubMed Articles [10 Associated PubMed Articles listed on BioPortfolio]

A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC).

Janssen Research & Development, LLC, part of the Janssen pharmaceutical companies of Johnson & Johnson, and NYU School of Medicine partnered to establish the Compassionate Use Advisory Committee (Comp...

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.

In recent years, the anti-CD38 monoclonal antibody daratumumab (Darzalex; Janssen-Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple myeloma, with the final res...

Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.

The article Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets, written by Brendan Mulhern, Yan Feng, Koonal Shah, Mathieu F. Janssen, Michael Herdman, Ben van Hout, Nancy Devlin was originally...

Effects of phrase and word frequencies in noun phrase production.

There is mounting evidence that the ease of producing and understanding language depends not only on the frequencies of individual words but also on the frequencies of word combinations. However, in t...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [17 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia ...

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering ...

Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder

The purpose of this study is to assess the usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in autism spectrum disorder (ASD) (severe abnorm...

A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt)and PARIET 20 mg DR tabs (JANS...

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Rivaroxaban from Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Indust...

Companies [34 Associated Companies listed on BioPortfolio]

Janssen-Cilag EMEA, EMHF, ESHA & ISG

Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N.V., is a research-based pharmaceutical company that develops and markets innovative, high-quality pharmaceutical products and services aim...

Janssen-Cilag International NV

Janssen-Cilag AG

NIL

Janssen-Cilag Farmacéutica

NIL

JANSSEN-ORTHO INC

Since 1961 Janssen-Cilag has been a member of the Johnson & Johnson family of companies. Founded in 1886, Johnson & Johnson today is the world's most comprehensive manufacturer of healthcare products ...

More Information about "Janssen-Cilag AG" on BioPortfolio

We have published hundreds of Janssen-Cilag AG news stories on BioPortfolio along with dozens of Janssen-Cilag AG Clinical Trials and PubMed Articles about Janssen-Cilag AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janssen-Cilag AG Companies in our database. You can also find out about relevant Janssen-Cilag AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record